ZODIAC

New Zealand Clinical Research is trialling an investigational medication that is being studied in participants of Rheumatoid Arthritis (RA).

ZB002 works by targeting and blocking a protein called TNF (tumour necrosis factor, also called “TNFα”), which is believed to play a role in diseases like RA. By blocking TNF, other similar medications have shown to reduce inflammation such diseases. ZB002 is designed to have a longer half-life (time it takes for the amount of drug in blood to reduce in half from its original amount), which should enable less frequent dosing for people who require the medication. 48 healthy participants have been dosed in the study already in Part A.

This study will investigate the effects of ZB002 in healthy participants (Part A) and in participants with RA (Part B). The purposes of Part B of this study are:

• Evaluate how safe and well tolerated ZB002 is, in participants with RA.
• Measure levels of ZB002 in the blood over time, following multiple doses.
• Measure the body’s response to multiple doses of ZB002.
• Assess the body’s immune response to ZB002.

It is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.

This study (2022 FULL 13422) is being funded by Zenas BioPharma., and has been approved by the Health and Disability Ethics Committee.

Study Visits:  16 visits

Reimbursement: $4,800 (less tax)